Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Search
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Empowering smallholder farmers
The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
CPHI Survey
CPHI Survey
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim
Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Mental Health
Human Pharma Clinical Pipeline Mental Health therapeutic area
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Really Digital, Mr Hach!
The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
respiratory_flyer_bio_05-2020.pdf
Respiratory_Flyer_BIO-2021.pdf
Respiratory Research and Development Timeline.pdf
Respiratory_Partnering_Interests_2018-12.pdf
Be At The Heart Of Every Breakthrough
Now is the time to cultivate your unique tech talent at a leading pharmaceutical company.
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Partnering for innovation in animal health
Collaboration with external partners is a fundamental part of our innovation strategy in Animal Health. Learn more about the partners we are looking for.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Biosecurity in farms: what’s this all about
Biosecurity is one of the three pillars we focus on: vaccination, biosecurity, and surveillance. But what is biosecurity in farms?
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.